These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 16495251

  • 21. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis.
    Lalitha P, Shapiro BL, Srinivasan M, Prajna NV, Acharya NR, Fothergill AW, Ruiz J, Chidambaram JD, Maxey KJ, Hong KC, McLeod SD, Lietman TM.
    Arch Ophthalmol; 2007 Jun; 125(6):789-93. PubMed ID: 17562990
    [Abstract] [Full Text] [Related]

  • 22. [In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole].
    Morera-López Y, Torres-Rodríguez JM, Jiménez-Cabello T.
    Rev Iberoam Micol; 2005 Jun; 22(2):105-9. PubMed ID: 16107169
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
    Marco F, Pfaller MA, Messer S, Jones RN.
    Antimicrob Agents Chemother; 1998 Jan; 42(1):161-3. PubMed ID: 9449278
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years.
    Pfaller MA, Carvalhaes CG, Messer SA, Rhomberg PR, Castanheira M.
    Diagn Microbiol Infect Dis; 2021 Nov; 101(3):115473. PubMed ID: 34352433
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. In vitro activities of a wide panel of antifungal drugs against various Scopulariopsis and Microascus species.
    Skóra M, Bulanda M, Jagielski T.
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5827-9. PubMed ID: 26100698
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
    Pfaller MA, Messer SA, Gee S, Joly S, Pujol C, Sullivan DJ, Coleman DC, Soll DR.
    J Clin Microbiol; 1999 Mar; 37(3):870-2. PubMed ID: 9986880
    [Abstract] [Full Text] [Related]

  • 37. Evaluation of antifungal susceptibility and clinical characteristics in fungal keratitis in a tertiary care center in North India.
    Vanathi M, Naik R, Sidhu N, Ahmed NH, Gupta N, Tandon R.
    Indian J Ophthalmol; 2022 Dec; 70(12):4270-4283. PubMed ID: 36453329
    [Abstract] [Full Text] [Related]

  • 38. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT, La Camera E, De Sarro A.
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [Abstract] [Full Text] [Related]

  • 39. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
    Johnson EM, Szekely A, Warnock DW.
    J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.